Moleculin Biotech (MBRX) News Today $0.82 -0.05 (-5.59%) Closing price 03:59 PM EasternExtended Trading$0.79 -0.03 (-3.30%) As of 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Moleculin Biotech doses first patient in Phase 3 MIRACLE trialApril 2 at 11:05 AM | finance.yahoo.comMoleculin Doses First Patient in Pivotal, Adaptive Phase 3 MIRACLE TrialApril 1 at 8:30 AM | globenewswire.comMoleculin Biotech files to sell 18.2M shares of common stock for holdersMarch 31, 2025 | markets.businessinsider.comEquities Analysts Set Expectations for MBRX FY2025 EarningsMarch 29, 2025 | americanbankingnews.comRoth Capital Issues Optimistic Estimate for MBRX EarningsMarch 28, 2025 | americanbankingnews.comMoleculin Biotech upgraded to Buy from Hold at MaximMarch 27, 2025 | markets.businessinsider.comMoleculin Biotech (NASDAQ:MBRX) Stock Rating Upgraded by StockNews.comMarch 27, 2025 | americanbankingnews.comMoleculin Biotech (NASDAQ:MBRX) Stock Rating Upgraded by Maxim GroupMarch 27, 2025 | americanbankingnews.comEarnings call transcript: Moleculin Biotech’s Q1 2025 updates on Anamycin trialsMarch 26, 2025 | uk.investing.comHC Wainwright Reaffirms Buy Rating for Moleculin Biotech (NASDAQ:MBRX)March 26, 2025 | americanbankingnews.comMaxim Group Upgrades Moleculin Biotech (MBRX)March 26, 2025 | msn.comMoleculin biotech highlights pivotal Phase 3 trials for Annamycin in AML with interim results expected in 2025March 25, 2025 | msn.comMoleculin Biotech, Inc. (NASDAQ:MBRX) Q4 2024 Earnings Call TranscriptMarch 25, 2025 | msn.comMoleculin Biotech, Inc. (MBRX) Q4 2024 Earnings Call TranscriptMarch 24, 2025 | seekingalpha.comMoleculin Biotech Shares Corporate Presentation UpdateMarch 24, 2025 | tipranks.comMoleculin Reports Full Year 2024 Financial Results and Provides Corporate UpdateMarch 24, 2025 | globenewswire.comMoleculin to Report Full Year 2024 Financial Results on March 21, 2025 and Host Conference Call and WebcastMarch 19, 2025 | globenewswire.comMoleculin Biotech, Inc. Participates in the Virtual Investor "Top 5 for '25" On-Demand ConferenceMarch 11, 2025 | prnewswire.comMoleculin to Present at the 37th Annual ROTH ConferenceMarch 10, 2025 | prnewswire.comMoleculin Biotech to be granted new patents for AnnamycinMarch 6, 2025 | markets.businessinsider.comMoleculin Announces Additional Annamycin Patent Allowances to Enhance Global ExclusivityMarch 6, 2025 | prnewswire.comMoleculin Biotech target adjusted to $8 from $45 at H.C. WainwrightMarch 3, 2025 | markets.businessinsider.comMoleculin Abstract Accepted for Poster Presentation at the Acute Leukemias XIX (ISALXIX) International SymposiumMarch 3, 2025 | prnewswire.comMoleculin Biotech announces pricing of $3.5M registered direct offeringFebruary 25, 2025 | markets.businessinsider.comMoleculin Announces Pricing of $3.5 Million Registered Direct Offering and Concurrent Private Placement Priced At The Market Under Nasdaq RulesFebruary 25, 2025 | prnewswire.comMoleculin Biotech (NASDAQ:MBRX) Stock, Short Interest ReportFebruary 14, 2025 | benzinga.comMoleculin Biotech secures $5.8 million from warrant exerciseFebruary 13, 2025 | msn.comWhy Is Blood Cancer Focused Moleculin Biotech Stock Trading More Than 400% On Thursday?February 13, 2025 | benzinga.comMoleculin Announces Exercise of Warrants for $5.8 Million Gross ProceedsFebruary 13, 2025 | prnewswire.comMoleculin Biotech receives positive FDA guidance for acceleration of AML trialFebruary 13, 2025 | markets.businessinsider.comMoleculin Receives Positive FDA Guidance for Acceleration of its Registration-Enabling MIRACLE Trial for R/R Acute Myeloid Leukemia (AML)February 13, 2025 | prnewswire.comMoleculin Biotech downgraded to Hold from Buy at MaximFebruary 13, 2025 | markets.businessinsider.comMoleculin Announces First European Approval for Phase 3 AML TrialFebruary 11, 2025 | msn.comMoleculin Biotech receives first approval in Europe for AML trial recruitingFebruary 11, 2025 | markets.businessinsider.comMoleculin Receives First Country Approval in Europe to Begin Recruiting for the MIRACLE Phase 3 R/R Acute Myeloid Leukemia (AML) Pivotal TrialFebruary 11, 2025 | prnewswire.comMoleculin Biotech reaches agreement to amend investor warrantsFebruary 10, 2025 | msn.comMBRX stock touches 52-week low at $1.46 amid sharp yearly declineJanuary 30, 2025 | msn.comMoleculin Participates in Virtual Investor "What This Means" SegmentJanuary 27, 2025 | prnewswire.comMoleculin Biotech (MBRX) Gets a Buy from Roth MKMJanuary 12, 2025 | markets.businessinsider.comMoleculin Biotech Shares Corporate Presentation UpdateJanuary 8, 2025 | tipranks.comMoleculin Highlights Development Progress of Annamycin, Phase 2 Data Outperforms Billion-Dollar Assets in AML, Phase 3 Data Readouts in 2025 & 2026January 8, 2025 | prnewswire.comMoleculin Biotech Releases Corporate Presentation UpdateDecember 19, 2024 | markets.businessinsider.comMoleculin Biotech Inc MBRXDecember 11, 2024 | morningstar.comMoleculin Evaluates Prelim. Activity Of Annamycin In Acute Ara-C, VEN Resistant Myeloid LeukemiaDecember 11, 2024 | markets.businessinsider.comMoleculin Announces Online Publication of Preclinical Data Demonstrating Significant Activity of Annamycin in Venetoclax Resistant AML ModelDecember 11, 2024 | prnewswire.comMoleculin Biotech Advances Annamycin for AML TreatmentNovember 18, 2024 | markets.businessinsider.comMoleculin Biotech announces new findings on AnnamycinNovember 18, 2024 | markets.businessinsider.comNew Findings Show Moleculin's Annamycin Overcomes Resistance to Venetoclax in AMLNovember 18, 2024 | prnewswire.comMoleculin Biotech Unveils New Corporate PresentationNovember 14, 2024 | tipranks.comMoleculin Accelerates Planned Unblinded Data Readout for MIRACLE Phase 3 R/R Acute Myeloid Leukemia (AML) Pivotal Trial to H2 2025November 14, 2024 | prnewswire.com Remove Ads Get Moleculin Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for MBRX and its competitors with MarketBeat's FREE daily newsletter. Email Address MBRX Media Mentions By Week MBRX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MBRX News Sentiment▼0.670.61▲Average Medical News Sentiment MBRX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MBRX Articles This Week▼52▲MBRX Articles Average Week Remove Ads Get Moleculin Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for MBRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies RPTX News Today CELU News Today XFOR News Today IPSC News Today VRCA News Today DYAI News Today IBIO News Today SPRO News Today BRNS News Today OTLK News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:MBRX) was last updated on 4/4/2025 by MarketBeat.com Staff From Our PartnersWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredThree new patents reveal Elon and Trump’s secret “Project America”Right now for a limited time… You can get Tim Bohen’s top 5 Trump stocks for 2025… For only ONE DOLLAR!...Timothy Sykes | SponsoredYour Retirement Is Caught in the CrossfireWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredCaught on Camera: Elon Musk’s “Area 51”You won’t believe what tech legend Jeff Brown found in what he calls Elon Musk’s “Area 51.” (Click here to see...Brownstone Research | SponsoredTrump’s Final Plan Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’...Porter & Company | SponsoredWall St. Icon: Looming Financial Tsunami Could Wipe Out the 1%Wall Street icon who forecasted Black Monday and dot-com crash says a new economic event could hit the America...InvestorPlace | SponsoredControversial opinion: Volume isn't enough.Don’t be fooled by volume alone — it's just one piece of the trading puzzle. High demand doesn’t matter if sup...MillPub | SponsoredRUTHLESS Musk Move >> coming June 1?Elon Musk has made headlines with everything from mass layoffs to political drama — but his next move could sh...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Moleculin Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Moleculin Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy MBRX Stock Free MBRX Stock Alerts